616 related articles for article (PubMed ID: 28579387)
1. Treatment advances in small cell lung cancer (SCLC).
Waqar SN; Morgensztern D
Pharmacol Ther; 2017 Dec; 180():16-23. PubMed ID: 28579387
[TBL] [Abstract][Full Text] [Related]
2. Progress and challenges in the treatment of small cell lung cancer.
Tartarone A; Giordano P; Lerose R; Rodriquenz MG; Conca R; Aieta M
Med Oncol; 2017 Jun; 34(6):110. PubMed ID: 28456992
[TBL] [Abstract][Full Text] [Related]
3. Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer.
Isobe Y; Sato K; Nishinaga Y; Takahashi K; Taki S; Yasui H; Shimizu M; Endo R; Koike C; Kuramoto N; Yukawa H; Nakamura S; Fukui T; Kawaguchi K; Chen-Yoshikawa TF; Baba Y; Hasegawa Y
EBioMedicine; 2020 Feb; 52():102632. PubMed ID: 31981983
[TBL] [Abstract][Full Text] [Related]
4. Management of small-cell lung cancer: incremental changes but hope for the future.
Hann CL; Rudin CM
Oncology (Williston Park); 2008 Nov; 22(13):1486-92. PubMed ID: 19133604
[TBL] [Abstract][Full Text] [Related]
5. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
Konala VM; Madhira BR; Ashraf S; Graziano S
Oncology; 2020; 98(11):749-754. PubMed ID: 32663833
[TBL] [Abstract][Full Text] [Related]
6. Current and future therapeutic approaches for the treatment of small cell lung cancer.
Rossi A; Tay R; Chiramel J; Prelaj A; Califano R
Expert Rev Anticancer Ther; 2018 May; 18(5):473-486. PubMed ID: 29544351
[TBL] [Abstract][Full Text] [Related]
7. Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.
Ragavan M; Das M
Curr Treat Options Oncol; 2020 Jun; 21(8):64. PubMed ID: 32601742
[TBL] [Abstract][Full Text] [Related]
8. Treatment of extensive-stage small cell lung carcinoma: current status and future prospects.
Demedts IK; Vermaelen KY; van Meerbeeck JP
Eur Respir J; 2010 Jan; 35(1):202-15. PubMed ID: 20044461
[TBL] [Abstract][Full Text] [Related]
9. Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine.
Van Den Borg R; Leonetti A; Tiseo M; Giovannetti E; Peters GJ
Expert Rev Anticancer Ther; 2019 Jun; 19(6):461-471. PubMed ID: 31148500
[No Abstract] [Full Text] [Related]
10. Advances in Small Cell Lung Cancer.
Kalemkerian GP; Schneider BJ
Hematol Oncol Clin North Am; 2017 Feb; 31(1):143-156. PubMed ID: 27912830
[TBL] [Abstract][Full Text] [Related]
11. NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018.
Kalemkerian GP; Loo BW; Akerley W; Attia A; Bassetti M; Boumber Y; Decker R; Dobelbower MC; Dowlati A; Downey RJ; Florsheim C; Ganti AKP; Grecula JC; Gubens MA; Hann CL; Hayman JA; Heist RS; Koczywas M; Merritt RE; Mohindra N; Molina J; Moran CA; Morgensztern D; Pokharel S; Portnoy DC; Rhodes D; Rusthoven C; Sands J; Santana-Davila R; Williams CC; Hoffmann KG; Hughes M
J Natl Compr Canc Netw; 2018 Oct; 16(10):1171-1182. PubMed ID: 30323087
[TBL] [Abstract][Full Text] [Related]
12. Role of Immune Checkpoint Inhibitors in Small Cell Lung Cancer.
Cooper MR; Alrajhi AM; Durand CR
Am J Ther; 2018; 25(3):e349-e356. PubMed ID: 29722737
[TBL] [Abstract][Full Text] [Related]
13. The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers.
Gelsomino F; Lamberti G; Parisi C; Casolari L; Melotti B; Sperandi F; Ardizzoni A
Cancer Treat Rev; 2019 Sep; 79():101887. PubMed ID: 31491661
[TBL] [Abstract][Full Text] [Related]
14. Therapies in the pipeline for small-cell lung cancer.
Romanidou O; Imbimbo M; Mountzios G; Abidin A; Morgillo F; Califano R
Br Med Bull; 2016 Sep; 119(1):37-48. PubMed ID: 27325208
[TBL] [Abstract][Full Text] [Related]
15. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.
Spigel DR; Socinski MA
J Thorac Oncol; 2013 May; 8(5):587-98. PubMed ID: 23546044
[TBL] [Abstract][Full Text] [Related]
16. Advances in the treatment of small-cell lung cancer.
Kalemkerian GP
Semin Respir Crit Care Med; 2011 Feb; 32(1):94-101. PubMed ID: 21500128
[TBL] [Abstract][Full Text] [Related]
17. Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer.
Udagawa H; Akamatsu H; Tanaka K; Takeda M; Kanda S; Kirita K; Teraoka S; Nakagawa K; Fujiwara Y; Yasuda I; Okubo S; Shintani M; Kosloski MP; Scripture C; Tamura T; Okamoto I
Lung Cancer; 2019 Sep; 135():145-150. PubMed ID: 31446987
[TBL] [Abstract][Full Text] [Related]
18. Prospects of targeted and immune therapies in SCLC.
Hendriks LEL; Menis J; Reck M
Expert Rev Anticancer Ther; 2019 Feb; 19(2):151-167. PubMed ID: 30590971
[No Abstract] [Full Text] [Related]
19. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study.
Blackhall F; Jao K; Greillier L; Cho BC; Penkov K; Reguart N; Majem M; Nackaerts K; Syrigos K; Hansen K; Schuette W; Cetnar J; Cappuzzo F; Okamoto I; Erman M; Langer SW; Kato T; Groen H; Sun Z; Luo Y; Tanwani P; Caffrey L; Komarnitsky P; Reinmuth N
J Thorac Oncol; 2021 Sep; 16(9):1547-1558. PubMed ID: 33607312
[TBL] [Abstract][Full Text] [Related]
20. Small Cell Lung Cancer.
Bernhardt EB; Jalal SI
Cancer Treat Res; 2016; 170():301-22. PubMed ID: 27535400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
